Prospective observational study on prediction of impaired glucose tolerance after initiation of glucocorticoid therapy for non-diabetic patients

Prospective observational study on prediction of impaired glucose tolerance after initiation of glucocorticoid therapy for non-diabetic patients - Prospective observational study on prediction of impaired glucose tolerance after initiation of glucocorticoid therapy for non-diabetic patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029225

Enrollment

Registered

2017-09-21

Start date

2017-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.without diabetes mellitus 2.20 years of age or older 3.start glucocorticoid therapy at a dose of 20 mg / day or more in terms of PSL for skin diseases or collagen diseases. 4.use glucocorticoid more than 28 days at the start 5.before the study, able to understand our explanation on the study and obtain the written informed consent based on their own free will

Exclusion criteria

Exclusion criteria: 1. Case of diabetes type at 75 g OGTT before glucocorticoid therapy. 2. Patients with severe renal dysfunction (serum Cre value before treatment start is greater than 1.5 mg / dl). 3. Cases with severe liver dysfunction (having decompensated cirrhosis or AST / ALT before treatment start more than 3 times higher than normal upper limit). 4. Cases with moderate inflammatory findings (CRP > 1.0 mg / dl or body temperature > 38.0). 5. Patients with gastrointestinal surgery history. 6. Case of using a calcineurin inhibitor. 7. Cases with malignant tumors and being treated. 8. Pregnancy, brestfeeding cases. 9. Other cases that the researcher deemed inappropriate.

Design outcomes

Primary

Measure	Time frame
Presence or absence of onset of glucocorticoid-induced hyperglycemia 28 days after glucocorticoid therapy	—

Countries

Japan

Contacts

Public ContactTomoko Yamada

Kobe University Hospital Division of Diabetes and Endocrinology

yamada@med.kobe-u.ac.jp078-382-5111

Outcome results